首頁(yè) > SCI期刊 > SCIE期刊 > JCRQ2 > 期刊介紹
評(píng)價(jià)信息:
影響因子:2.6
年發(fā)文量:21
《肝病醫(yī)學(xué)證據(jù)與研究》(Hepatic Medicine-evidence And Research)是一本以GASTROENTEROLOGY & HEPATOLOGY綜合研究為特色的國(guó)際期刊。該刊由Dove Medical Press出版商該刊已被國(guó)際重要權(quán)威數(shù)據(jù)庫(kù)SCIE收錄。期刊聚焦GASTROENTEROLOGY & HEPATOLOGY領(lǐng)域的重點(diǎn)研究和前沿進(jìn)展,及時(shí)刊載和報(bào)道該領(lǐng)域的研究成果,致力于成為該領(lǐng)域同行進(jìn)行快速學(xué)術(shù)交流的信息窗口與平臺(tái)。該刊2023年影響因子為2.6。
Hepatic Medicine Evidence and Research is an international peer-reviewed medical journal dedicated to liver disease, dedicated to publishing clinical studies, case reports, reviews, and expert opinions on liver disease. This journal emphasizes evidence-based medical practice, aiming to provide scientific basis for the prevention, diagnosis, and treatment of liver diseases. It covers research on various liver diseases, from viral hepatitis to fatty liver, cirrhosis, and liver cancer, and is an important source of information for liver specialists and researchers.
The characteristic of the magazine lies in its emphasis on high-quality clinical research, which can directly affect clinical decision-making and patient care. The editorial committee of the journal is composed of internationally renowned liver disease experts, ensuring the scientific and practical nature of the published articles. In addition, the journal is indexed in multiple databases, including PubMed Central, which increases its visibility and influence in the international medical community. It is one of the authoritative journals in the field of liver disease and a valuable resource for medical professionals who wish to access the latest clinical research and treatment progress. By reading this journal, professionals can maintain an understanding of the latest research in the field of liver disease treatment and apply this knowledge to their daily clinical practice.
《肝病醫(yī)學(xué)證據(jù)與研究》是一本專注于肝臟疾病的國(guó)際同行評(píng)審醫(yī)學(xué)期刊,它致力于發(fā)表關(guān)于肝臟疾病的臨床研究、病例報(bào)告、綜述和專家意見(jiàn)等內(nèi)容。該期刊強(qiáng)調(diào)基于證據(jù)的醫(yī)療實(shí)踐,旨在為肝臟疾病的預(yù)防、診斷和治療提供科學(xué)依據(jù)。它覆蓋了從病毒性肝炎到脂肪肝、肝硬化以及肝癌等多種肝臟疾病的研究,是肝臟??漆t(yī)生和研究人員的重要信息來(lái)源。
雜志的特點(diǎn)在于其對(duì)高質(zhì)量臨床研究的重視,這些研究能夠直接影響臨床決策和患者護(hù)理。期刊的編輯委員會(huì)由國(guó)際知名的肝臟疾病專家組成,確保了發(fā)表文章的科學(xué)性和實(shí)用性。此外,該期刊被多個(gè)數(shù)據(jù)庫(kù)收錄,包括PubMed Central,這增加了其在國(guó)際醫(yī)學(xué)界的可見(jiàn)度和影響力。它是肝臟疾病領(lǐng)域的權(quán)威期刊之一,對(duì)于希望獲取最新臨床研究和治療進(jìn)展的醫(yī)療專業(yè)人員來(lái)說(shuō),是一個(gè)寶貴的資源。通過(guò)閱讀該期刊,專業(yè)人士可以保持對(duì)肝臟疾病治療領(lǐng)域最新研究的了解,并將這些知識(shí)應(yīng)用于日常的臨床實(shí)踐中。
如果您需要協(xié)助投稿或潤(rùn)稿服務(wù),您可以咨詢我們的客服老師。我們專注于期刊咨詢服務(wù)十年,熟悉發(fā)表政策,可為您提供一對(duì)一投稿指導(dǎo),避免您在投稿時(shí)頻繁碰壁,節(jié)省您的寶貴時(shí)間,有效提升發(fā)表機(jī)率,確保SCI檢索(檢索不了全額退款)。我們視信譽(yù)為生命,多方面確保文章安全保密,在任何情況下都不會(huì)泄露您的個(gè)人信息或稿件內(nèi)容。
JCR分區(qū)等級(jí):Q2
按JIF指標(biāo)學(xué)科分區(qū) | 收錄子集 | 分區(qū) | 排名 | 百分位 |
學(xué)科:GASTROENTEROLOGY & HEPATOLOGY | ESCI | Q2 | 67 / 143 |
53.5% |
按JCI指標(biāo)學(xué)科分區(qū) | 收錄子集 | 分區(qū) | 排名 | 百分位 |
學(xué)科:GASTROENTEROLOGY & HEPATOLOGY | ESCI | Q3 | 96 / 143 |
33.22% |
Gold OA文章占比 | 研究類文章占比 | 文章自引率 |
100.00% | 61.90% | |
開(kāi)源占比 | 出版國(guó)人文章占比 | OA被引用占比 |
名詞解釋:JCR分區(qū)在學(xué)術(shù)期刊評(píng)價(jià)、科研成果展示、科研方向引導(dǎo)以及學(xué)術(shù)交流與合作等方面都具有重要的價(jià)值。通過(guò)對(duì)期刊影響因子的精確計(jì)算和細(xì)致劃分,JCR分區(qū)能夠清晰地反映出不同期刊在同一學(xué)科領(lǐng)域內(nèi)的相對(duì)位置,從而幫助科研人員準(zhǔn)確識(shí)別出高質(zhì)量的學(xué)術(shù)期刊。
歷年IF值(影響因子)
歷年引文指標(biāo)和發(fā)文量
歷年自引數(shù)據(jù)
若用戶需要出版服務(wù),請(qǐng)聯(lián)系出版商。